Related references
Note: Only part of the references are listed.CYP2B6*6 genotype and high efavirenz plasma concentration but not nevirapine are associated with low lumefantrine plasma exposure and poor treatment response in HIV-malaria-coinfected patients
B. A. Maganda et al.
PHARMACOGENOMICS JOURNAL (2016)
Malaria prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women
Ritah F. Mutagonda et al.
MALARIA JOURNAL (2016)
SLCO1B1 Gene Variations Among Tanzanians, Ethiopians, and Europeans: Relevance for African and Worldwide Precision Medicine
Eleni Aklillu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2016)
The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment
Betty A. Maganda et al.
MALARIA JOURNAL (2015)
Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex
Fazleen H. M. Hatta et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2015)
Population Pharmacokinetics and Clinical Response for Artemether-Lumefantrine in Pregnant and Nonpregnant Women with Uncomplicated Plasmodium falciparum Malaria in Tanzania
Dominic Mosha et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment
E. Ngaimisi et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
High CYP2A6 Enzyme Activity as Measured by a Caffeine Test and Unique Distribution of CYP2A6 Variant Alleles in Ethiopian Population
Eleni Aklillu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2014)
Effect of Single Nucleotide Polymorphisms in Cytochrome P450 Isoenzyme and N-Acetyltransferase 2 Genes on the Metabolism of Artemisinin-Based Combination Therapies in Malaria Patients from Cambodia and Tanzania
Eva Maria Staehli Hodel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda
Joel Tarning et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes
Jin Sol Leel et al.
KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY (2013)
Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations
Eliford Ngaimisi et al.
PLOS ONE (2013)
Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients
A. Habtewold et al.
PHARMACOGENOMICS JOURNAL (2013)
Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda
F. Kloprogge et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2013)
Population Pharmacokinetics of Dihydroartemisinin and Piperaquine in Pregnant and Nonpregnant Women with Uncomplicated Malaria
Joel Tarning et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Liver Enzyme Abnormalities and Associated Risk Factors in HIV Patients on Efavirenz-Based HAART with or without Tuberculosis Co-Infection in Tanzania
Sabina Mugusi et al.
PLOS ONE (2012)
Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis
E. Ngaimisi et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
The pharmacogenetics of antimalaria artemisinin combination therapy
Rita Piedade et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians
E. Gebeyehu et al.
PHARMACOGENOMICS JOURNAL (2011)
Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes
Hyunyoung Jeong
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2010)
Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial
Patrice Piola et al.
LANCET INFECTIOUS DISEASES (2010)
Genetic Variations in ABCB1 and CYP3A5 as well as Sex Influence Quinine Disposition Among Ugandans
Jackson K. Mukonzo et al.
THERAPEUTIC DRUG MONITORING (2010)
Variation of Drug Kinetics in Pregnancy
Petr Pavek et al.
CURRENT DRUG METABOLISM (2009)
Multiplexed Real-Time PCR Assay for Discrimination of Plasmodium Species with Improved Sensitivity for Mixed Infections
Sandra E. Shokoples et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2009)
Understanding the pharmacokinetics of Coartem (R)
Abdoulaye Djimde et al.
MALARIA JOURNAL (2009)
African Genetic Diversity: Implications for Human Demographic History, Modern Human Origins, and Complex Disease Mapping
Michael C. Campbell et al.
Annual Review of Genomics and Human Genetics (2008)
Clinical pharmacology of artemisinin-based combination therapies
Francesca T. Aweeka et al.
CLINICAL PHARMACOKINETICS (2008)
4β-Hydroxycholesterol is a new endogenous CYP3A marker:: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
Ulf Diczfalusy et al.
PHARMACOGENETICS AND GENOMICS (2008)
A Randomised Controlled Trial of Artemether-Lumefantrine Versus Artesunate for Uncomplicated Plasmodium falciparum Treatment in Pregnancy
Rose McGready et al.
PLOS MEDICINE (2008)
Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance
Stephen A. Ward et al.
LANCET INFECTIOUS DISEASES (2007)
The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria
Rose McGready et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2006)
CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population
Rajaa A. Mirghani et al.
PHARMACOGENETICS AND GENOMICS (2006)
Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles
C Rodríguez-Antona et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Pregnancy-induced changes in pharmacokinetics - A mechanistic-based approach
GD Anderson
CLINICAL PHARMACOKINETICS (2005)
The CYP3A4*1B allele increases risk for small cell lung cancer:: effect of gender and smoking dose
H Dally et al.
PHARMACOGENETICS (2003)
Increased transcriptional activity of the CYP3A4* 1B promoter variant
B Amirimani et al.
ENVIRONMENTAL AND MOLECULAR MUTAGENESIS (2003)
Genetic contribution to variable human CYP3A-mediated metabolism
JK Lamba et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
JA Williams et al.
DRUG METABOLISM AND DISPOSITION (2002)
Pharmacokinetics in pregnancy
M Dawes et al.
BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY (2001)
Share Paper
